Corbus Pharmaceuticals Holdings, Inc. (LON:0SZI)
London · Delayed Price · Currency is GBP · Price in USD 7.35
-0.09 (-1.21%)
Feb 12, 2026, 4:54 PM GMT
LON:0SZI Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
28
Market Cap
106.50M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 881.71K | -3.06M | -77.61% |
| Dec 31, 2020 | 3.94M | -32.21M | -89.11% |
| Dec 31, 2019 | 36.14M | 31.32M | 649.51% |
| Dec 31, 2018 | 4.82M | 2.38M | 97.62% |
| Dec 31, 2017 | 2.44M | 528.77K | 27.66% |
| Dec 31, 2016 | 1.91M | 1.26M | 194.80% |
| Dec 31, 2015 | 648.38K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.64B |
| GSK plc | 32.67B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| EKF Diagnostics Holdings | 50.22M |
| Diaceutics | 34.40M |
| Venture Life Group | 31.23M |
| Shield Therapeutics | 30.29M |
Corbus Pharmaceuticals Holdings News
- 2 months ago - Cormorant Asset Management, LP Reduces Stake in Corbus Pharmaceuticals Holdings Inc - GuruFocus
- 2 months ago - Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data Transcript - Seeking Alpha
- 2 months ago - Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data - Slideshow - Seeking Alpha
- 2 months ago - Corbus Pharmaceuticals (CRBP) Reports Phase 1 Study Results for Obesity Drug - GuruFocus
- 2 months ago - CRBP: Corbus Pharmaceuticals' Promising Phase I Study Sparks Interest - GuruFocus
- 2 months ago - Corbus Reports Positive Phase 1a Results Of CRB-913 In Obesity, Stock Surges - Update - Nasdaq
- 2 months ago - Corbus Pharmaceuticals (CRBP) Advances Obesity Treatment with CRB-913 Trials - GuruFocus
- 2 months ago - Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss - GlobeNewsWire